Would you like to react to this message? Create an account in a few clicks or log in to continue.

Tessera Therapeutics - gene writing (Flagship Pioneering, Editas Medicine, Intellia Therapeutics, Casebia Therapeutics, Beam Therapeutics, Seres Therapeutics, Bayer, Moderna)

Post new topic   Reply to topic

Go down

Tessera Therapeutics - gene writing (Flagship Pioneering, Editas Medicine, Intellia Therapeutics, Casebia Therapeutics, Beam Therapeutics, Seres Therapeutics, Bayer, Moderna) Empty Tessera Therapeutics - gene writing (Flagship Pioneering, Editas Medicine, Intellia Therapeutics, Casebia Therapeutics, Beam Therapeutics, Seres Therapeutics, Bayer, Moderna)

Post by Abacus Fri Feb 19, 2021 3:29 am

(May 5, 2015) White-Hot Flagship Ventures Inks Deals With AstraZeneca PLC, Bayer CropScience AG and Nestle SA As VC Roars
White-hot venture capital and venture creation firm Flagship Ventures
is having a stellar week, saying Tuesday it has formed three new strategic partnerships with AstraZeneca PLC ,
Nestlé Health Science and Bayer CropScience, as a raging biotech sector continues to roar.
Flagship’s notable companies are varied and include a stable of at least three VentureLabs companies: Moderna Therapeutics,
which focuses on messenger RNA Therapeutics; Seres Health, studying microbial ecosystems; and Symbiota, pioneering plant microbiome solutions.

(July 7, 2020) This Company Wants to Rewrite the Future of Genetic Disease
Tessera has spent the past two years developing a new class of molecular manipulators
capable of doing lots of things Crispr can do—and some that it can’t, including precisely plugging in long stretches of DNA.
It’s not gene editing, says von Maltzahn. It’s “gene writing.”
The company hasn’t yet demonstrated that any of its gene writers can eliminate an inherited disease.
But in mouse models, the team has consistently been able to use them to insert lots of copies
of a large green fluorescent protein gene into the animals’ genomes as a way of proving that they can reliably place designer DNA.
Now, scientists have been making animals artificially glow for decades.
What’s different about Tessera’s method is that company’s scientists only need to inject a bit of RNA to make it happen.
The ability to inject just a piece of RNA, similar to the approach taken by one of the leading Covid-19 vaccinemakers, Moderna,
could make it easier for researchers to go after genetic conditions in which the treatment involves adding big chunks of reparative genetic code.

(July 9, 2020) Tessera Therapeutics Aims to Rewrite DNA with New Age Gene Manipulators
Tessera Therapeutics is an early-stage life sciences company that was founded by Geoffrey von Maltzahn, MIT-trained biological engineer,
Jacob Rubens, an MIT trained synthetic biologist and other scientists at Flagship Labs in 2018
with an idea of creating a platform that could design, make, and launch gene writing medicines.
The company holds a 30-person R&D team that has deep genetic medicine
and startup expertise, including alumni from Editas, Intellia, Beam, Casebia, and Moderna.

Tessera’s gene writers are based on two different types of MGEs.
One that can cut itself from its original location and integrate to a different location (transposons)
and second, which can make its copy and transport the copy to a new location, creating a duplicate of itself (retrotransposons).
Guarding the mobile elements are special sequences on either end that defines MGE’s boundaries.
In between the boundaries are the genes for proteins that recognize these boundaries and cut them
when transposon is moving out or copy them via an RNA intermediate into a new location.

Since its inception in 2018, Tessera has been searching genome sequences of thousands of bacterial species
for these mobile genetic elements and modifying them to create new gene editors capable of producing any desired protein.
Following this modification, MGE’s can be administered into desired tissue by lipid nanoparticles or AAV vectors,
which will eventually cut or copy and paste protein-coding DNA pieces in any genomic location.

(January 12, 2021) Tessera Therapeutics scores $230M to ramp up 'gene writing' tech to cure disease
Tessera Therapeutics is pioneering “gene writing,” a kind of genetic medicine it hopes will surmount the limitations of gene editing
and gene therapy—and investors have bet more than $230 million on the approach.
At its core, gene writing simply means writing short or long messages into the genome
to treat disease, said Tessera CEO Geoffrey von Maltzahn, Ph.D.
“What that allows is one to be able to cure or prevent a disease from ever happening by writing in the code of DNA,
which of course drives the biology in every single cell in the body,”
he said. Tessera is developing multiple ways to do it.


Back to top Go down

Back to top

Permissions in this forum:
You can reply to topics in this forum